Hjem › Burkitts lymfom › Kansas
Burkitts lymfom kliniske forsøg i Kansas
6 studier for Burkitts lymfom søger deltagere på steder i Kansas.
Byer i Kansas
Officiel studietekst (engelsk)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
- Cancer Center of Kansas - Wichita, Wichita
RekruttererFase 3
Alder 18 til 39 · Alle køn · Opdateret 2. okt. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT03739814Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Wesley Medical Center, Wichita
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Mercy Hospital, Kansas City
RekruttererFase 2
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 1 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT07069699Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
- University of Kansas Cancer Center, Westwood
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. maj 2026 · NCT06879340Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.